Financial Comparison: TherapeuticsMD (TXMD) and AbbVie (ABBV)
TherapeuticsMD (NASDAQ: TXMD) and AbbVie (NYSE:ABBV) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.
This is a breakdown of recent recommendations for TherapeuticsMD and AbbVie, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
TherapeuticsMD presently has a consensus target price of $14.88, suggesting a potential upside of 196.91%. AbbVie has a consensus target price of $90.67, suggesting a potential upside of 1.08%. Given TherapeuticsMD’s stronger consensus rating and higher probable upside, equities research analysts plainly believe TherapeuticsMD is more favorable than AbbVie.
Institutional & Insider Ownership
68.3% of AbbVie shares are held by institutional investors. 0.2% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
AbbVie pays an annual dividend of $2.56 per share and has a dividend yield of 2.9%. TherapeuticsMD does not pay a dividend. AbbVie pays out 62.9% of its earnings in the form of a dividend. AbbVie has increased its dividend for 44 consecutive years.
This table compares TherapeuticsMD and AbbVie’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares TherapeuticsMD and AbbVie’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|TherapeuticsMD||$18.26 million||55.98||-$88.99 million||N/A||N/A|
|AbbVie||$26.71 billion||5.35||$11.57 billion||$4.07||22.04|
AbbVie has higher revenue and earnings than TherapeuticsMD.
AbbVie beats TherapeuticsMD on 10 of the 14 factors compared between the two stocks.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc. is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.
AbbVie Company Profile
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
Receive News & Stock Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related stocks with our FREE daily email newsletter.